



2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential

Ian Olver¹ · Rebecca Clark-Snow² · Christina H. Ruhlmann³ · Maria-Angeles Garcia-del-Barrio⁴ · Lee Schwartzberg⁵ · Bernardo Leon Rapoport^{6,7} · Franziska Jahn⁸

Accepted: 1 December 2023

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023

Abstract

Purpose Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential.

Methods A working group performed a systematic literature review using Medline, Embase, and Scopus databases between June 2015 and January 2023 of the management of antiemetic prophylaxis for anticancer therapy of low or minimal emetic potential. A consensus committee reviewed recommendations and required a consensus of 67% or greater and a change in outcome of at least 10%.

Results Of 293 papers identified, 15 had information about managing systemic cancer treatment regimens of low or minimal emetic potential and/or compliance with previous management recommendations. No new evidence was reported that would change the current MASCC recommendations. No antiemetic prophylaxis is recommended for minimal emetic potential therapy, and single agents recommended for low emetic potential chemotherapy for acute emesis, but no prophylaxis is recommended for delayed emesis. Commonly, rescue medication includes antiemetics prescribed for the next higher level of emesis.

Conclusion There is insufficient data to change the current guidelines. Future studies should seek to more accurately determine the risk of emesis with LEC beyond the emetogenicity of the chemotherapy to include patient-related risk assessment.

Keywords Guidelines · Nausea · Vomiting · Chemotherapy · Low emetogenicity · Minimal emetogenicity

Introduction

The major predictor used to determine whether a patient will experience nausea and/or vomiting after receiving systemic therapy for cancer has been the emetic potential of

the therapy. With drugs classified as having minimal emetic potential, the risk is < 10%, while those classified as low emetogenic potential (LEC) had a risk of emesis of 10 to 30% if no antiemetics are given [1, 2].

✉ Ian Olver
ian.olver@adelaide.edu.au
Bernardo Leon Rapoport
bernardo.rapoport@up.ac.za
Franziska Jahn
franziska.jahn@uk-halle.de

¹ Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South 5000, Australia

² Oncology Supportive Care Consultant, Overland Park, KS 66212, USA

³ Department of Oncology, Odense University Hospital, Odense, Denmark

⁴ Pharmacy Department, School of Pharmacy and Nutrition, Clínica Universidad de Navarra, Universidad de Navarra, Madrid Headquarters Madrid, Spain

⁵ Reno College of Medicine, University of Nevada, Reno, NV, USA

⁶ The Medical Oncology Centre of Rosebank, 129 Oxford Road, Saxonwold 2196, Johannesburg, South Africa

⁷ Department of Immunology, Faculty of Health Sciences, University of Pretoria, Corner Doctor Savage Road and Bophelo Road, Pretoria 0002, South Africa

⁸ Department of Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

Many oral agents fit into these categories, and many of the new targeted and immunotherapies have been classified as having minimal risk of emesis or LEC [3, 4]. However, there are many agents where there is a lack of data to be able to classify their emetogenicity, and more research is needed that specifically documents the risk of nausea and vomiting over time.

Comparing recent updated guidelines of ASCO and NCCN with 2016 MASCC/ESMO guidelines shows no change in the recommendations of no prophylactic antiemetics for systemic anticancer agents with minimal risk. For low-risk regimens, ASCO recommends single-agent 5HT3 receptor antagonists or steroids. In contrast, NCCN and MASCC/ESMO also include other single agents, such as dopamine antagonists for acute emesis but no additional prophylaxis for delayed emesis [3, 5].

This paper reviews the recent literature to update the previous MASCC guidelines of 2016 for controlling nausea and vomiting with systemic cancer treatment of minimal emetic potential and LEC [6].

Methods

Searches were performed in the Medline, Embase, and Scopus databases, for papers published between June 1, 2015, and June 2022 and then extended to January 2023. The search terms were cancer AND antiemetics AND low OR minimal emetogenicity AND cancer chemotherapy, and filters restricting papers to humans, English language, and adults 19+ years. Papers must report new information management of antiemetics for cancer therapy of low to minimal risk or/and compliance with management guidelines. To mitigate the risk of bias, two reviewers (IO and RCS) assessed the full-text papers and identified the relevant papers for the review, which were shared with the seven members of the working group who analyzed the content of the manuscripts to enable recommendations to be made. The systematic literature review followed the PRISMA guidelines for reporting [7].

The recommendations were presented to the whole consensus committee, which discussed, modified, and finally approved the recommendations.

Results

Of 293 papers identified from the three databases, 15 were judged relevant with information about the management of systemic cancer treatment regimens of low or minimal emetic potential and/or compliance with previous management recommendations (Fig. 1). No new evidence was reported that would change the current MASCC

recommendations for the management of systemic cancer treatment of low or minimal emetic potential.

However, several issues were raised because it was clear that some patients were being overtreated, usually with regimens recommended for moderately emetogenic chemotherapy. Such regimens are also employed to rescue those patients who experienced emesis despite receiving guideline approve antiemetics. Other patients experienced emesis and were therefore undertreated despite complying with recommendations [8, 9]. This led to a discussion about identifying higher-risk patients and what treatment they should receive.

Recommendations

Prevention of acute nausea and vomiting in patients receiving low emetogenic chemotherapy

A single antiemetic agent, such as dexamethasone, a 5-HT3 receptor antagonist, or a dopamine receptor antagonist, such as metoclopramide, may be considered for prophylaxis in patients receiving chemotherapy of low emetic risk.

Level of evidence: II.

Grade of recommendation: B

Prevention of acute nausea and vomiting in patients receiving minimally emetogenic chemotherapy

No antiemetic should be routinely administered before chemotherapy to patients without a history of nausea and vomiting.

Level of evidence: IV.

Grade of recommendation: D

Prevention of delayed nausea and vomiting in patients receiving low or minimally emetogenic chemotherapy

No antiemetic should be administered for the prevention of delayed nausea and vomiting induced by low or minimal emetogenic chemotherapy.


Level of evidence: IV.

Grade of recommendation: D

Discussion

Although few studies have provided evidence for strategies for managing antiemesis with regimens of low and minimal emetic potential and, therefore, no change in the antiemetic recommendations, several recent studies report on compliance with current guidelines, which highlight the real-world antiemetic usage in these groups.

Fig. 1 PRISMA flow diagram



Major causes of overuse of antiemetics occurred with LEC where two antiemetic agents, often a 5-hydroxytryptamine type 3 receptor antagonist (5HT3RA) and a steroid, were used when the recommendation was just for a single agent, and in the minimal emetic potential where single agents or a 5HT3RA and steroid were used where no prophylactic antiemetics were recommended [9–12]. Under-usage usually occurred where steroids were omitted in patients receiving low emetic potential chemotherapy [13]. Concordance with guidelines can change as guidelines are updated, as occurred with low emetic risk chemotherapy when the ASCO guidelines changed between 2006 and 2017, allowing 5HT3 receptor antagonists, and concordance in a Japanese study increased from 5.9 to 57.9% reflecting this change [13].

Studies have had mixed outcomes regarding whether guideline compliance affects chemotherapy-induced nausea and vomiting (CINV) outcomes. An international review and, more recently, Kandasamy et al., in an Indian study, found that clinicians' guideline adherence was greater when the antiemetics used in practice complied with antiemetic guidelines. Also, the CINV outcomes were better [14, 15]. However, Caracuel et al., in a study from Spain, and Nikbakht et al. from Iran could not show that antiemetic guideline adherence reduced CINV [10, 12]. Indeed, though, cost-effectiveness increased from reducing the overuse of antiemetics [9].

Can guideline adherence be improved? Araz M et al., surveying the Turkish Oncology Group, did not find any characteristic of the practitioners, age, gender, experience, or

academic status which predicted adherence to guidelines for low acute or delayed emetic chemotherapy [16]. Active education was proposed to increase guideline adherence. Paradoxically, education increased the improper prescribing of 5HT3RA for the prophylaxis of low emetic chemotherapy in an Italian study [17]. In contrast, Grunberg et al. on reviewing barriers to implementation of antiemetic guidelines concluded that the use of a local opinion leader or an in-house education program only had a short-term impact on practice [18]. Similarly, the ASCO Choosing Wisely guidelines only had a short-term impact on antiemetic prescribing except in the low-risk intravenous group, where it was more prolonged, but not in the antiemetic usage in the minimal-risk group [8]. Affronti et al., however, found that standardized order sets for the antiemetics with audit feedback significantly improved compliance in patients with glioma [19].

A major focus of recent studies is whether in determining antiemetic usage other risk factors than the emetogenicity of the chemotherapy should be considered. This has been the case with the selection of specific antiemetics. For example, in treating pancreatic cancer, steroid exposure may need to be minimized to avoid the development of diabetes [20]. In choosing a suitable regimen, salvaging low- and minimal-risk regimens has involved moving to the drug recommended for the next higher level of emesis [21]. There are successful salvage regimens for low emetic chemotherapy both in the acute and delayed phase, which spare steroids by using palonosetron. This suggests that this single agent could be used for low-emetic chemotherapy when steroid sparing is desirable [22, 23]. Likewise, olanzapine has been shown to be effective in patients with refractory LEC [24].

A significant advancement in reducing the overuse or underuse of antiemetics with low and minimal risk. Chemotherapy would be the ability to predict the risk of emesis in individual patients more accurately. This may entail adding personal risk factors to the emetic risk of the chemotherapy. Dranitsaris and Petrella published a prediction tool for identifying patients at high risk for nausea and vomiting after chemotherapy analyzing multiple factors, but their application is complex in routine practice and, as it is different for acute and delayed emesis, it is even less practical [25, 26]. A prospective Japanese study of 222 patients undergoing LEC showed, in a multivariate analysis, that a prior history of nausea and receiving chemotherapy other than taxanes were independent risk factors associated with nausea and vomiting [27]. This study did not show younger age or sex to be a risk factor.

In a study of 95 patients, 26.3% received LEC, and 40% of those experienced nausea. We need to better identify those patients with a risk of nausea and achieve better control in LEC patients. The patient characteristics which increased the risk of nausea in this study were being female, having an age of less than 60 years, and having

a history of motion sickness or morning sickness [28]. Investigators in clinical trials should report levels of nausea and vomiting even when grade 1 or 2 to ascertain the level of prophylactic antiemetics to be prescribed more accurately.

Conclusions

There is insufficient data to change the guidelines for controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. No prophylactic antiemetics are recommended for patients receiving chemotherapy of minimal emetic potential. Single agents are recommended for acute emesis but not to prevent delayed emesis with chemotherapy of low emetic potential. More data should be collected on the emetogenicity of new agents, particularly oral targeted therapies and immunotherapy. Future studies should seek to more accurately determine the risk of emesis with LEC beyond the emetogenicity of the chemotherapy to include patient-related risk assessment.

Author contribution The initial draft was written by IO and all authors revised it critically for its intellectual content.

All authors reached agreement on the recommendations, are accountable for the accuracy and integrity of the work, and have approved the version to be published.

Data Availability All data supporting the findings of this study are available within the paper and its publicly available references.

Declarations

Conflict of interest Schwartzberg COI: Consultant, Helsinn, GlaxoSmithKline, Pfizer. The other authors have no relevant financial or non-financial interests to declare.

References

1. Hesketh PJ, Kris KG, Grunberg SM et al (1977) Proposal for classifying the acute emetogenicity of cancer chemotherapy. *J Clin Oncol* 15:103–109
2. Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to Clinical practice. *Oncologist* 4(3):191–196
3. Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. *J Clin Oncol* 38:2782–2797
4. Jordan K, Chan A, Gralla R, Jahn F, Rapoport B, Ruhlmann CH, Sayegh P, Hesketh PJ (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents – Updated MASCC/ESMO consensus recommendation. *Support Care Cancer* (in press)
5. Razvi Y, Chan S, McFarlane T et al (2019) ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting. *Support Care Cancer* 27:87–95

6. Olver I, Ruhlman C, Jahn F et al (2017) 2016 Updated MASCC/ESMO consensus recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. *Support Care Cancer* 25:297–301
7. Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guidelines for reporting systematic reviews. *BMJ* 372:n71. <https://doi.org/10.1136/bmj.n71>
8. Encinosa W, Davidoff AJ (2017) Changes in antiemetic overuse in response to choosing wisely recommendations. *JAMA Oncol* 3:320–326
9. Okuyama A, Nakamura F, Higashi T (2017) Prescription of prophylactic antiemetic drugs for patients receiving chemotherapy with minimal and low emetic risk. *JAMA Oncol* 3:344–350
10. Caracuel F, Muñoz N, Baños U, Ramirez G (2015) Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital. *J Oncol Pharm Practice* 21:163–169
11. Ebrahimi M, Mehrzad V, Moghaddas A (2020) Adherence to ASCO for prophylaxis of acute chemotherapy-induced nausea and vomiting. *Asian Pac J Cancer Prev* 21:1567–1572
12. Nikbakht Z, Rajabi M, Shahrabi A, Roohi E, Hashemian F (2021) Evaluation of adherence to antiemetic treatment guidelines in patients with chemotherapy-induced nausea and vomiting in teaching hospitals in Iran. *J Canc Edu* 36:1022–1029
13. Bun S, Kunisawa S, Sasaki N et al (2019) Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database. *Cancer Med* 8(14):6243–6249
14. Kandasamy G, Sivanandy P, Khobrani M et al (2019) Effectiveness of antiemetics in the management of chemotherapy-induced nausea and vomiting in cancer patients following chemotherapy guidelines. *Indian J Pharm Sci* 81:757–765
15. Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. *Eur J Pharmacol* 722:197–202
16. Araz M, Karaagac M, Korkmaz L et al (2019) The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group. *Curr Probl cancer* 43:344–353
17. Roila F (2004) Transferring scientific evidence to oncological practice: a trial of three different implementation strategies on antiemetic prescriptions. *Support Care Cancer* 12:446–453
18. Grunberg SM (2009) Obstacles to the Implementation of Antiemetic Guidelines. *J Natl Compr Canc Netw* 7:601–605
19. Affronti ML, Schneider SM, Herndon JE et al (2014) Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence in to practice. *Support Care Cancer* 22:1897–1905
20. Ohata K, Fujii H, Sadaka S et al (2021) Comparison of chemotherapy-induced nausea and vomiting between gemcitabine plus nab-paclitaxel combination chemotherapy and gemcitabine monotherapy in patients with advanced pancreatic cancer. *Anticancer Res* 41:3643–3648
21. De las Peñas R, Blasco A, De Castro J et al (2016) SEOM clinical guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016). *Clin Transl Oncol* 18:1237–1242
22. Okada Y, Oba K, Furukawa N et al (2019) One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. *Oncologist* 24:1593–1600
23. Hesketh PJ, Morrow G, Aw K et al (2021) Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC). *Support Care Cancer* 20:2633–2637
24. Vig S, Siebert L, Green MR (2014) Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity. *J Cancer Res Clin Oncol* 140:77–82
25. Dranitsaris G, Joy A, Young SD, Clemons M, Callaghan W, Petrella T (2009) Identifying patients at high risk of nausea and vomiting after chemotherapy. The development of a practical predicting tool I. Acute nausea and vomiting. *J Support Oncol* 7
26. Petrella T, Clemons M, Joy A, Young S, Callaghan W, Dranitsaris G (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool II. Delayed nausea and vomiting. *J Support Oncol* 7
27. Hayashi T, Shimokawa M, Miyoshi T et al (2017) A prospective, observational, multicentre study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. *Support Care Cancer* 25:2707–2714
28. Smit T, Kotze I, du Plessis J (2021) The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy. *Ann Palliat Med* 10:2679–2686

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.